DK2119452T3 - Farmaceutisk sammensætning, omfattende et anti-cd6-monoklonal antistof anvendt ved diagnosticering og be-handling af rheumatoid arthritis - Google Patents

Farmaceutisk sammensætning, omfattende et anti-cd6-monoklonal antistof anvendt ved diagnosticering og be-handling af rheumatoid arthritis Download PDF

Info

Publication number
DK2119452T3
DK2119452T3 DK07855983.8T DK07855983T DK2119452T3 DK 2119452 T3 DK2119452 T3 DK 2119452T3 DK 07855983 T DK07855983 T DK 07855983T DK 2119452 T3 DK2119452 T3 DK 2119452T3
Authority
DK
Denmark
Prior art keywords
diagnosis
treatment
pharmaceutical composition
monoclonal antibody
rheumatoid arthritis
Prior art date
Application number
DK07855983.8T
Other languages
English (en)
Inventor
Casimiro José Enrique Montero
Herrera Zaima Mazorra
Ramirez Ruby Alonso
Rodriguez Rolando Perez
Parada Ángel Raimundo Casaco
Original Assignee
Ct Inmunologia Molecular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Inmunologia Molecular filed Critical Ct Inmunologia Molecular
Application granted granted Critical
Publication of DK2119452T3 publication Critical patent/DK2119452T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK07855983.8T 2006-12-26 2007-12-24 Farmaceutisk sammensætning, omfattende et anti-cd6-monoklonal antistof anvendt ved diagnosticering og be-handling af rheumatoid arthritis DK2119452T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CU20060250 2006-12-26
PCT/CU2007/000021 WO2008077355A1 (es) 2006-12-26 2007-12-24 Composición farmaceutica que comprende un anticuerpo monoclonal anti-cd6 utilizado en el diagnóstico y tratamiento de la artritis reumatoide

Publications (1)

Publication Number Publication Date
DK2119452T3 true DK2119452T3 (da) 2020-04-20

Family

ID=39562112

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07855983.8T DK2119452T3 (da) 2006-12-26 2007-12-24 Farmaceutisk sammensætning, omfattende et anti-cd6-monoklonal antistof anvendt ved diagnosticering og be-handling af rheumatoid arthritis

Country Status (19)

Country Link
US (3) US20100092423A1 (da)
EP (1) EP2119452B1 (da)
KR (1) KR101482956B1 (da)
CN (2) CN101657215A (da)
AR (1) AR064527A1 (da)
AU (1) AU2007336563B2 (da)
CA (1) CA2676185C (da)
DK (1) DK2119452T3 (da)
ES (1) ES2785043T3 (da)
HK (1) HK1213782A1 (da)
IT (1) ITTO20070942A1 (da)
MY (1) MY165625A (da)
NZ (1) NZ578635A (da)
PE (1) PE20081553A1 (da)
PL (1) PL2119452T3 (da)
PT (1) PT2119452T (da)
RU (1) RU2472526C2 (da)
UY (1) UY30838A1 (da)
WO (1) WO2008077355A1 (da)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009113083A1 (en) 2008-03-14 2009-09-17 Biocon Limited A monoclonal antibody and a method thereof
EP2371863A1 (en) * 2010-03-30 2011-10-05 Pierre Fabre Médicament Humanized anti CXCR4 antibodies for the treatment of cancer
US11037196B2 (en) 2012-02-24 2021-06-15 Netclearance Systems, Inc. Interactive advertising using proximity events
US11062258B2 (en) 2012-02-24 2021-07-13 Netclearance Systems, Inc. Automated logistics management using proximity events
PL3024485T3 (pl) 2013-07-23 2021-06-14 Biocon Limited Zastosowanie partnera wiążącego cd6 i oparty na tym sposób
CA2978976C (en) * 2015-03-13 2024-05-14 Jiangsu Hengrui Medicine Co., Ltd. Anti-sclerostin antibody, antigen binding fragment and medical use thereof
AU2017217814A1 (en) * 2016-02-10 2018-08-23 Cayman Chemical Company Incorporated Anti-citrullinated HLA polypeptide antibodies and uses thereof
US11242401B2 (en) 2016-10-21 2022-02-08 Biocon Limited Monoclonal antibody and a method of use for the treatment of lupus
US11334889B2 (en) 2016-11-29 2022-05-17 Netclearance Systems, Inc. Mobile ticketing based on proximity
US11151534B2 (en) * 2016-11-29 2021-10-19 Netclearance Systems, Inc. Consumer interaction module for point-of-sale (POS) systems
CN109903854B (zh) * 2019-01-25 2023-04-07 电子科技大学 一种基于中医药文献的核心药物识别方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US699755A (en) 1902-03-06 1902-05-13 Ira G Hoag Train-order box in connection with semaphores.
US6162432A (en) * 1991-10-07 2000-12-19 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
EP0631783A1 (en) * 1993-06-03 1995-01-04 Mitsubishi Chemical Corporation Antiviral combinations of 2',3'-di-deoxyribonucleosides with 6-benzyl-1-ethoxymethyl-5-substituted uracil derivatives
CA2175247A1 (en) * 1993-11-02 1995-05-11 Barton F. Haynes Cd6 ligand
US5423562A (en) * 1993-11-05 1995-06-13 Pearce, Jr.; Fredric C. Chair lift
CU22615A1 (es) * 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
CU22584A1 (es) * 1995-11-17 1999-11-03 Centro Inmunologia Molecular Composiciones farmacéuticas que contienen un anticuerpo monoclonal que reconoce el antígeno de diferenciación leucocitario humano cd6 y sus usos para el diagnóstico y tratamiento de la psoriasis
ATE207889T1 (de) * 1996-03-20 2001-11-15 Aventis Pharma Sa Trizyclische verbindungen mit wirkung auf integrine, besonders auf das alphavbeta3-integrin,verfahren zur ihrer herstellung und zwischenprodukte des verfahrens, ihre verwendung als arzneimittel und sie enthaltende pharmazeutische zusammensetzungen
WO1998043089A1 (en) * 1997-03-03 1998-10-01 Bristol-Myers Squibb Company Monoclonal antibodies to human cd6
JP2002544174A (ja) * 1999-05-07 2002-12-24 ジェネンテック・インコーポレーテッド Ｂ細胞表面マーカーに結合するアンタゴニストを用いた自己免疫疾患の治療
FI110553B (fi) * 2001-02-12 2003-02-14 Perlos Oyj Liitin ja liittimen irtopala
ES2192128B1 (es) * 2001-04-27 2005-01-01 Universidad De Vigo Anticuerpo monoclonal humano que reconoce especificamente la molecula humana cd69, y su uso en terapia.
KR20070072502A (ko) * 2004-09-29 2007-07-04 코와 가부시키가이샤 관절 류머티즘의 예방 및/또는 치료약
AU2005304624B2 (en) * 2004-11-12 2010-10-07 Xencor, Inc. Fc variants with altered binding to FcRn
ES2359567T3 (es) * 2004-12-29 2011-05-24 Yuhan Corporation Anticuerpo humanizado específico para el factor de necrosis tumoral-alfa.

Also Published As

Publication number Publication date
PE20081553A1 (es) 2008-12-10
KR20090122910A (ko) 2009-12-01
PL2119452T3 (pl) 2021-03-08
US20170066835A1 (en) 2017-03-09
US20160024220A1 (en) 2016-01-28
KR101482956B1 (ko) 2015-01-15
UY30838A1 (es) 2008-07-31
AU2007336563A1 (en) 2008-07-03
RU2472526C2 (ru) 2013-01-20
CA2676185A1 (en) 2008-07-03
ES2785043T3 (es) 2020-10-05
AR064527A1 (es) 2009-04-08
WO2008077355A1 (es) 2008-07-03
PT2119452T (pt) 2020-05-08
EP2119452B1 (en) 2020-03-04
AU2007336563B2 (en) 2012-11-01
ITTO20070942A1 (it) 2008-06-27
RU2009128659A (ru) 2011-02-10
NZ578635A (en) 2012-03-30
EP2119452A1 (en) 2009-11-18
EP2119452A4 (en) 2012-06-06
CN101657215A (zh) 2010-02-24
CA2676185C (en) 2013-03-12
US20100092423A1 (en) 2010-04-15
CN105251004A (zh) 2016-01-20
HK1213782A1 (zh) 2016-07-15
MY165625A (en) 2018-04-18

Similar Documents

Publication Publication Date Title
DK2119452T3 (da) Farmaceutisk sammensætning, omfattende et anti-cd6-monoklonal antistof anvendt ved diagnosticering og be-handling af rheumatoid arthritis
DK3002298T3 (da) Anti-faktor xi monoklonale antistoffer og fremgangsmåder til anvendelse deraf
CY2021009I1 (el) Αντισωματα αντι-ρ-σελεκτινης και μεθοδοι χρησης αυτων στην αντιμετωπιση φλεγμονωδων νοσων
DK2061814T3 (da) Antistoffer og immunokonjugater og anvendelse deraf.
CY2018013I2 (el) Ανθρωπινα anti-il-23 αντισωματα, συνθεσεις, μεθοδοι και χρησεις
DK2907827T3 (da) Humaniserede anti-faktor D-antistoffer og anvendelser deraf
DK1994055T3 (da) Anti-5t4-antistoffer og anvendelser deraf
DK1896073T3 (da) Anti-il-antistoffer, sammensætninger, fremgangsmåder og anvendelser
NO344992B1 (no) Anti-GM-CSF antistoffer og anvendelser for disse
DK2059535T3 (da) Prlr-specifikt antistof og anvendelser deraf
DK2342233T3 (da) Anti-CXCR4-antistoffer og anvendelse deraf i behandling af cancer
DK1904104T3 (da) SP35-antistoffer og anvendelser heraf
HK1199047A1 (en) Il-31 monoclonal antibodies and methods of use il-31
BRPI0818437A2 (pt) Anticorpo ou fragmento funcional do anticorpo, composição farmacêutica, uso de pelo menosum dos anticorpos ou fragmentos funcionais dos anticorpos, e, hibridoma
IL186659A0 (en) Il-31 monoclonal antibodies and methods of use
EP1940466A4 (en) ANTI-ADDL MONOCLONAL ANTIBODIES AND THEIR USE
IL212633A (en) A monoclonal antibody or its antigen-binding portion, its pharmaceutical preparations and its use in the preparation of cancer drugs
DK3345927T5 (da) Humant monoklonalt antistof Human CD134 (OX40) og fremgangsmåder til frembringelse og anvendelse deraf
DK1948693T3 (da) Monoklonale antistoffer mod claudin-18 til behandling af cancer
DK2124999T3 (da) Activin-actrii antagonister og anvendelser til behandling af anæmi
DK2034830T3 (da) Anti-vla-1-antistof til behandling af slagtilfælde
DK1817055T3 (da) Ovr110-antistofsammensætninger og fremgangsmåder til anvendelse heraf
CY2018021I2 (el) Αντισωμα anti-fgf23 και φαρμακευτικη συνθεση που το περιλαμβανει
NO345083B1 (no) Humaniserte anti-CS1 Ig G1-antistoffer til bruk for behandling av multippelt myelom, og anvendelse av slike for fremstilling av et medikament for behandling av multippelt myelom.
DK1976884T3 (da) Anti-ephrinb2-antistoffer og fremgangsmåder til anvendelse deraf.